Responses to Message Source and Presentation Using Psychophysiology

July 14, 2025 updated by: Donghee Nicole Lee, University of Massachusetts, Worcester

Identifying and Examining the Effects of Source and Presentation on Responses to Electronic Cigarette Public Education Messages in Young Adult Vapers and Non-vapers - Part 2

The goal of this clinical trial is to use psychophysiological methods to test the effects of a message source (expert and peer) and message presentation types (one-sided and two-sided) to identify the optimal message type for young adults who vape and do not vape.

Study Overview

Study Type

Interventional

Enrollment (Actual)

112

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Worcester, Massachusetts, United States, 01605
        • UMass Chan Medical School Shaw Building

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Ages 18-24
  • Fluent in English
  • Either vaping in the past 30 days or not having vaped in the past 30 days but susceptible to vaping
  • Self-reported abstinence of combusted tobacco or marijuana at time of visit

Exclusion Criteria:

  • Ages below 18 or above 24
  • Not fluent in English
  • Not confirmed self-reported abstinence of combusted tobacco or marijuana at time of visit

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Expert, one-sided
Participants assigned to the expert, one-sidedness condition will receive one-sided e-cigarette messages from an expert source.
Participants will view a brief description of an expert source and see one-sided e-cigarette education messages.
Experimental: Expert, two-sided
Participants assigned to the expert, two-sidedness condition will receive two-sided e-cigarette messages from an expert source.
Participants will view a brief description of an expert source and see two-sided e-cigarette education messages.
Experimental: Peer, one-sided
Participants assigned to the peer, one-sidedness condition will receive one-sided e-cigarette messages from a peer source.
Participants will view a brief description of a peer source and see one-sided e-cigarette education messages.
Experimental: Peer, two-sided
Participants assigned to the peer, two-sidedness condition will receive two-sided e-cigarette messages from a peer source.
Participants will view a brief description of a peer source and see two-sided e-cigarette education messages.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual Attention
Time Frame: The entire duration of message from beginning of its delivery to the completion of viewing, up to 45 minutes.
Visual attention was assessed by measuring dwell time, which is the length of time participants spent on looking at the specific areas of interest (AOIs) collected in miliseconds. Dwell time values were collected for 18 messages, and aggregated to provide the average dwell time scores for each arm. This was done for each vaping status (current vapers and susceptible non-vapers). Higher dwell time scores indicate higher visual attention, indicating better message outcomes.
The entire duration of message from beginning of its delivery to the completion of viewing, up to 45 minutes.
Allocation of Cognitive Resources
Time Frame: Baseline and immediately after viewing all the messages (approximately 45 minutes).
Heart rate values were collected in beats per minute (BPM) on a per-second basis during the presentation of each 18 distinct messages as well as during the immediately preceding black screen (baseline) for each message. Descriptive statistics were used to summarize changes in the BPM values during the message exposure period by comparing the BPM values collected during each message second to the BPM values collected during the immediately preceding baseline period. These change scores were then averaged across all messages within each study arm to generate a mean BPM value per condition, and this was done for each vaping status (current vapers and susceptible non-vapers). Lower BPM values reflect greater cognitive response, therefore indicate better message outcomes.
Baseline and immediately after viewing all the messages (approximately 45 minutes).
Arousal
Time Frame: Baseline and immediately after viewing all the messages (approximately 45 minutes).
Galvanic Skin Response (GSR) values were recorded in microsiemens on a per-second basis during the presentation of each 18 distinct messages as well as during the immediately preceding black screen (baseline) for each message. Descriptive statistics were used to summarize changes in GSR values by comparing each message response to its preceding baseline period. These change scores were then averaged across all messages within each study arm to generate a mean GSR score per condition, and this was done for each vaping status group (current vapers and susceptible non-vapers). Higher GSR values reflect greater physiological arousal, and indicate better message outcomes.
Baseline and immediately after viewing all the messages (approximately 45 minutes).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Attitudes
Time Frame: After exposure to all messages, approximately up to 45 minutes.
Participants' self-reported vaping attitudes were measured by using a five-point bipolar scale using 7 subscale items assessing whether participants thought vaping was enjoyable, healthy, safe, fun, smart, cool, and attractive on a scale from 1 (negative attitudes) to 5 (positive attitudes). Items were summed and averaged to create a single composite score, and this was done for each arm for each vaping status. Higher scores indicate more positive e-cigarette attitudes, therefore worse outcomes.
After exposure to all messages, approximately up to 45 minutes.
Behavioral Intentions
Time Frame: After exposure to all messages, approximately up to 45 minutes.
Participants' vaping intentions was measured by using a 3 subscale items assessing participants' intentions to vape: soon/anytime during the next year/would use offered by one of their best friends, on a scale from 1 (Definitely not) to 5 (Definitely yes). Items were summed and averaged to create a single composite score. This was done for each vaping status (current vapers and susceptible non-vapers). Higher scores indicate greater vaping intentions, therefore indicating worse outcome.
After exposure to all messages, approximately up to 45 minutes.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Donghee N Lee, PhD, University of Massachusetts, Worcester

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 18, 2024

Primary Completion (Actual)

June 10, 2024

Study Completion (Actual)

June 10, 2024

Study Registration Dates

First Submitted

January 17, 2024

First Submitted That Met QC Criteria

February 16, 2024

First Posted (Actual)

February 21, 2024

Study Record Updates

Last Update Posted (Actual)

August 1, 2025

Last Update Submitted That Met QC Criteria

July 14, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY00001223
  • 1K99CA281094-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vaping

Clinical Trials on Expert, one-sided

Subscribe